(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Vera Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast VERA's revenue for 2026 to be $1,602,612,228, with the lowest VERA revenue forecast at $164,026,819, and the highest VERA revenue forecast at $3,389,036,612. On average, 5 Wall Street analysts forecast VERA's revenue for 2027 to be $11,996,296,073, with the lowest VERA revenue forecast at $4,756,139,516, and the highest VERA revenue forecast at $28,056,244,897.
In 2028, VERA is forecast to generate $27,420,050,605 in revenue, with the lowest revenue forecast at $15,270,450,088 and the highest revenue forecast at $49,957,335,542.